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Prospective, double-blind, placebo-controlled 
trial of low-dose amiodarone in patients with 
severe heart failure and asymptomatic frequent 
ventricular ectopy 
Sudden cardiac death is a common cause of mortality in patients with congestive heart failure. 
To determine if low-dose amiodarone could reduce sudden death among these patients, a 
prospective, placebo-controlled, double-blind pilot trial was conducted. One hundred one patients 
with ejection fractions <30%, New York Heart Association class III or IV symptoms, and frequent 
but asymptomatic spontaneous ventricular ectopy (Lown class II to V) were randomly assigned to 
treatment with low-dose amiodarone (400 mg/day for 4 weeks and then 200 mg/day) or placebo. 
Mean follow-up was 357 days (range 4 to 1009 days). Side effects were infrequent and there was 
no difference in the incidence of side effects between the treatment groups. The frequency of 
spontaneous ventricular ectopy in the group receiving amiodarone fell from 4992 it 1240 
beats/24 hours at baseline to 1135 & 494 beats/24 hours after 1 month of treatment (p = 0.02) 
and remained low after 6 months, while there was no change in ventricular ectopy among the 
patients receiving placebo. Despite the reduction in ectopy, there was no improvement in 
mortality or decrease in the Incidence of sudden death. One-year mortallty by Kaplan-Meier 
analysis was 26% in the group receiving amiodarone and 19% In the group receiving placebo 
(p = NS). One-year mortallty in patlents with >75% reduction in ventricular ectopy after 1 month 
of treatment was 31% versus 17% in patients with 175% ectopic suppression (p = NS). Although 
the size of the trial and its statlstical power do not eliminate the possibility of a slgnlflcant 
reduction in mortality with low-dose amiodarone, any effect is likely to be modest, i.e., <25%. 
Therefore low-dose amiodarone can be safely administered to patients wlth severely impaired 
myocardlal function and will significantly suppress spontaneous ventricular ectopy. However, 
despite arrhythmia suppression, low-dose amiodarone may not reduce or may have only a modest 
effect on the incidence of sudden death in patients with heart failure and asymptomatic 
ventricular ectopy. (AM HEART J 1991;122:1016.) 
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Sudden cardiac death has been reported to account 
for nearly half of the mortality among patients with 
congestive heart failure. i-l1 Although the pathophys- 
iology is unknown, these sudden deaths are thought 
to be caused by malignant ventricular arrhythmias. 
In an attempt to prevent sudden death and improve 
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survival, antiarrhythmic therapy is often prescribed 
prophylactically. However, the effect of antiarrhyth- 
mic agents on the incidence of sudden death and 
overall mortality in patients with heart failure has 
not been tested in controlled trials. Therefore we 
conducted a prospective, double-blind pilot trial 
comparing treatment with the antiarrhythmic drug, 
amiodarone, versus placebo in patients with conges- 
tive heart failure and frequent asymptomatic ven- 
tricular ectopy to determine the safety of the treat- 
ment regimen, the feasibility of carrying out a large- 
scale mortality trial with an agent with the potential 
to cause serious toxicity, and to gain initial insight 
into the likelihood of reducing the incidence of sud- 
den death with this agent. 
1016 
Volume 122 
Number 4, Part 1 Low-dose amiodarone in CHF 1017 
METHODS Table 1. Baseline clinical characteristics 
Patients. Patients ages 21 years or older with congestive 
heart failure referred to the University of Michigan Hospi- 
tal, the Veterans Administration Hospital in Ann Arbor, or 
the Hammersmith Hospital in London were eligible for 
study. The entry criteria were: (1) New York Heart Asso- 
ciation (NYHA) class III or IV heart failure symptoms; (2) 
left ventricular ejection fraction 130 % ; and (3) Lown class 
II to V ventricular ectopy recorded during 24-hour ambu- 
latory electrocardiographic monitoring. Patients were ex- 
cluded if they had a history of symptoms attributable to 
ventricular ectopy including lightheadedness, dizziness, 
syncope, or if they were already receiving antiarrhythmic 
drugs. Patients with palpitations were not excluded. All 
patients gave informed written consent as approved by 
their hospital’s Committee for Human Subjects. The study 
population consisted of 101 patients, 86 men and 15 
women, aged 26 to 78 years (mean 57 years). 
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Study design. Forty-nine patients were randomly cho- 
sen to receive amiodarone and 52 to receive placebo. The 
dose of amiodarone was 400 mg/day orally for 4 weeks, fol- 
lowed by a maintenance oral dose of 200 mg/day. The study 
medication was administered in a double-blind fashion. 
Serial chest roentgenograms, electrocardiograms, and se- 
rum potassium and magnesium levels were obtained every 
3 months. Chest roentgenograms were examined for evi- 
dence of interstitial fibrosis. The development of heart 
block or intraventricular conduction delay was assessed 
from the electrocardiograms. Abnormalities in serum elec- 
trolyte levels were immediately corrected with oral supple- 
mentation. To avoid digitalis toxicity, the dose of digoxin 
was reduced to 0.125 mg/day in patients receiving >0.125 
mg/day of digoxin. Patients were specifically queried for 
symptoms of photosensitivity, tremor, ataxia, nausea, and 
constipation every 3 months. Follow-up 24-hour ambula- 
tory monitoring was performed after 1 month and after 6 
months of study to assess suppression of ventricular 
ectopics and complex ventricular ectopy including couplets 
and ventricular tachycardia. Ventricular tachycardia was 
defined as three or more consecutive ventricular ectopics at 
a mean rate 2 120 beats/min. Side effect and survival data 
were reviewed by a safety committee (MAS and BP), 
blinded by group, at B-month intervals. 
All data were analyzed according to the intention- 
to-treat principle. Differences in baseline characteristics 
between treatment groups were analyzed by the Student’s 
t test or by Fisher’s exact test. Kaplan-Meier product limit 
estimates were used to compare the survival of each treat- 
ment group. Savage (Mantel-Cox) statistics were used to 
assess the significance of associations between baseline 
characteristics and survival. 
RESULTS 
The trial was designed for a mean follow-up of 1 year. 
Sample size calculations were based on the following 
assumptions: (1) The l-year cardiovascular mortality rate 
in the control population would be 60%. (2) Sudden deaths 
would account for 50% of total deaths. (3) Amiodarone 
would reduce the incidence of sudden death at 1 year by 
50% and improve survival at 1 year by 25 % . 
Data analysis. Patient deaths were classified as (1) sud- 
den, if the patient deteriorated and died within 1 hour of 
the onset of symptoms; (2) progressive, if patient deterio- 
ration began >l hour prior to death; (3) infarction-related, 
if death occurred within 1 week of an acute myocardial in- 
farction; or (4) noncardiac. Patients were withdrawn from 
the study and were considered to have survived sudden 
death if they experienced syncope caused by documented 
ventricular tachycardia or if unexplained syncope oc- 
curred. 
Clinical characteristics. There were no significant 
differences between treatment groups in baseline 
clinical characteristics (Table I). The average ejec- 
tion fraction of the study population was <20%. A 
greater proportion of patients had NYHA class III 
(n = 83) than NYHA class IV symptoms (n = 18). 
The average frequency of ventricular ectopy was 
4900 + 830 beats/24 hours. Sixty-two percent of the 
patients had asymptomatic ventricular tachycardia 
recorded during baseline monitoring. No patient had 
an abnormal serum potassium or magnesium level at 
the time of entry into the study. Symptoms of con- 
gestive heart failure had been present for 32 * 4 
months. Medical therapy included digoxin in 45 % , 
loop diuretics (either furosemide or bumetanide) in 
90 % , potassium-sparing diuretics (either amiloride, 
triamterene, or spironolactone) in 36%) and an- 
giotensin-converting enzyme inhibitors in 64 % . Base- 
line characteristics were similar between hospitals 
except that digoxin was more commonly adminis- 
tered to patients treated at the University and Vet- 
erans Hospitals than at the Hammersmith Hospital. 
Side effects. Patients were followed for between 4 
and 1009 days (mean 357 days). No patient developed 
interstitial fibrosis or a peripheral neuropathy during 
the trial. Heart block occurred in one patient receiv- 
ing amiodarone and appeared to initiate sudden 
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Fig. 1. Relative frequency and complexity of ventricular 
ectopy in patients receiving amiodarone (solid bars) or 
placebo (hatched bars) at baseline and after 1 and 6 
months of treatment. There were no statistically signifi- 
cant differences between treatment groups at baseline. Af- 
ter 1 month, total premature ventricular contractions 
(PVC’s), couplets, and ventricular tachycardia were sig- 
nificantly less frequent in the patients receiving amio- 
darone compared with those receiving placebo, p = 0.02, 
0.01, and 0.002, respectively. Similarly, the frequency of 
ventricular ectopy decreased from baseline in patients re- 
ceiving amiodarone but remained unchanged in those 
receiving placebo (*p < 0.05; **p < 0.02). 
death. The incidence of other side effects was similar 
in both groups. A total of 12 patients discontinued 
their study medication, seven in the amiodarone 
group and five in the placebo group. Reasons for dis- 
continuation among patients receiving amiodarone 
included: tremor (n = 2), non-photosensitive rash 
(n = l), threefold elevation in hepatic enzymes 
(n = l), new onset atria1 fibrillation (n = l), and re- 
location to another country (n = 2). Reasons for 
withdrawal among patients receiving placebo in- 
cluded: non-photosensitive rash (n = l), threefold 
elevation in hepatic enzymes (n = l), new onset atria1 
fibrillation (n = l), and cardiac transplantation 
(n = 2). Two patients, one from each treatment 
group, were lost to follow-up. 
Ventricular ectopic suppression. Significant sup- 
pression of ventricular ectopy in patients treated 
with amiodarone was observed after 1 month and af- 
ter 6 months of study (Fig. 1). The frequency of ven- 
tricular ectopics in the group receiving amiodarone 
was reduced from 4992 -t 1240 beats/24 hours at 
baseline to 1135 f 494 beats/24 hours after 1 month 
(p = 0.02) and to 1686 + 770 beats/24 hours after 6 
months (p = 0.14). Suppression of more than 75% of 
DARONE -I 
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Fig. 2. Kaplan-Meier survival curves for the amiodarone 
and placebo groups. There was no statistically significant 
difference between survival in the two groups. 
all ventricular ectopics was achieved in 60% of the 
patients receiving amiodarone after 1 month and in 
75% after 6 months. In contrast, the frequency of 
ventricular ectopics did not change significantly in 
the group receiving placebo, from 4816 +- 1139 
beats/24 hours at baseline to 4489 f 1040 beats/24 
hours after 1 month (p = NS) and 4213 f 1246 
beats/24 hours after 6 months (p = NS). 
Complex ventricular ectopy was also reduced after 
1 month and after 6 months of treatment in the group 
receiving amiodarone. The frequency of couplets in 
the group receiving amiodarone was reduced from 
145 k 59 couplets/24 hours at baseline to 32 k 27 
couplets/24 hours after 1 month Cp = NS) and to 
70 k 40 couplets/24 hours after 6 months (p = 0.04). 
The frequency of couplets did not change signifi- 
cantly in the group receiving placebo, from 185 _t 95 
couplets/24 hours at baseline to 156 t- 51 couplets/24 
hours after 1 month (p = NS) and to 242 +- 114 cou- 
plets/24 hours after 6 months (p = NS). The propor- 
tion of patients with asymptomatic ventricular ta- 
chycardia on 24-hour ambulatory monitoring who 
received amiodarone was 52 % at baseline and 21% 
(p = 0.01) and 33% (p = NS) after 1 month and af- 
ter 6 months of study, respectively. Among patients 
who received placebo, the proportion with asymp- 
tomatic ventricular tachycardia was 71% at baseline 
and 64% (p = NS) and 60% (p = NS) after 1 and af- 
ter 6 months, respectively. 
Study end points. Twenty-six patients died or sur- 
vived episodes of sudden death during the trial. All 
deaths were considered to be cardiovascular and no 
deaths occurred following infarction. Five deaths 
were classified as progressive pump failures; two of 
these patients were receiving amiodarone and three 
were receiving placebo (p = NS). Twenty-one pa- 
tients died suddenly; 12 of them were receiving ami- 
odarone and nine were receiving placebo (p = NS). 
Five of the 21 patients who experienced sudden death 
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Fig. 3. Absolute and relative mortality in the amiodarone 
and placebo groups at 1 year. The 80% (hatched bar) and 
90% (solid bar) confidence limits are shown assuming a l- 
year control mortality of 19%. 
survived; two who were receiving amiodarone and 
three who were receiving placebo (p = NS). 
Two patients receiving amiodarone died unexpect- 
edly while undergoing ambulatory monitoring. One 
of these patients died in his sleep with progressive 
bradycardia over 30 minutes’ duration, ending in 
asystole. The other patient suffered complete heart 
block without a ventricular escape rhythm. Neither 
patient had reported previous lightheadedness or 
syncope and neither had experienced any symptom- 
atic deterioration in exercise tolerance or resting 
dyspnea. 
Survival. There was no difference in the survival 
rates between treatment groups (Fig. 2). At 1 year, 
the overall mortality rate was 24% -28% in the 
group receiving amiodarone and 19% in the group 
receiving placebo (p = NS). The absolute and rela- 
tive differences between groups in l-year mortality 
and the statistical power of the trial are illustrated in 
Fig. 3. 
There was also no significant difference in survival 
between treatment groups in either the ischemic or 
nonischemic subpopulations (Fig. 4). At 1 year, the 
mortality rate among patients with ischemic heart 
disease was 34 % for those receiving amiodarone and 
19% for those receiving placebo (p = NS). The l-year 
mortality among patients with nonischemic cardio- 
myopathies was 24 % versus 27 % (p = NS) in those 
receiving amiodarone and placebo, respectively. 
Suppression of spontaneous ventricular ectopy was 
not associated with an improved prognosis. Patients 
with greater than 75% suppression of baseline ectopy 
after 1 month were compared with patients with less 
suppression (Fig. 5). Four patients died within 1 
month of randomization (one receiving amiodarone 
and three receiving placebo) before undergoing a 
second 24-hour ambulatory recording to assess the 
degree of ectopic suppression. At 1 year, the mortal- 
I) \b’S 
Fig. 4. Kaplan-Meier survival curves for patients receiv- 
ing amiodarone and placebo subgrouped by etiology. There 
were no significant differences in survival between treat- 
ment groups in either the ischemic or nonischemic popu- 
lations. There was also no significant difference in survival 
between the ischemic and nonischemic populations. 
loo 2cm 3lYJ ‘ml 500 
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Fig. 5. Kaplan-Meier survival curves for patients whose 
total ventricular ectopy was markedly suppressed (>75% 
reduction) after 1 month of treatment versus patients 
whose ectopy was not suppressed (~75% reduction). 
There was no significant difference in survival between 
these subgroups based on arrhythmia suppression. 
ity rate among patients with >75% suppression was 
23% versus 17% (p = NS) among those with less 
suppression. 
Survival was inversely related to the duration of 
symptomatic heart failure (p = 0.0065) and New 
York Heart Association functional class (p = 0.033). 
Survival was not related to age, sex, ejection fraction, 
etiology of the cardiomyopathy, serum levels of 
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potassium or magnesium, or treatment with loop di- 
uretics, potassium-sparing diuretics, digoxin, an- 
giotensin-converting enzyme inhibitors, nitrates, or 
calcium channel blockers. 
DISCUSSION 
This study has shown that a low dose of amio- 
darone can be safely administered to patients with 
severely impaired left ventricular function and 
NYHA class III or IV symptoms of congestive heart 
failure. This dose of amiodarone effectively sup- 
pressed ventricular ectopy. However, despite ar- 
rhythmia suppression, amiodarone did not reduce 
the incidence of sudden death or improve survival. 
Safety of low-dose amiodarone. The low dose of 
amiodarone used in this study appeared to be safe for 
patients with severe heart failure. No patient devel- 
oped a serious side effect and equal numbers of pa- 
tients discontinued amiodarone and placebo. Other 
investigators have also reported that low-dose amio- 
darone is well tolerated and is not associated with the 
development of pulmonary toxicity or peripheral 
neuropathy.12-l4 
However, previous reports of the safety of low-dose 
amiodarone in heart failure patients suggest that the 
incidence of some side effects may be dose-depen- 
dent. For example, Hamer et a1.r2 reported that low- 
dose amiodarone (600 mg/day for 2 weeks followed by 
200 mglday maintenance dosage) improved exercise 
tolerance in 16 patients with severe left ventricular 
dysfunction and was safe. Nevertheless, nausea was 
a significant problem in their study and caused 25 % 
of the patients to discontinue amiodarone within 6 
months. Most of their patients developed nausea 
during the 2-week loading phase when they were re- 
ceiving 600 mg/day of amiodarone. In contrast, nau- 
sea may have been avoided in our study by using a 
lower loading dose of the medication (400 mg/day). 
Neri et a1.13 reported that low-dose amiodarone (600 
mg/day for 1 week, 400 mg/day for 1 week, followed 
by a 200 to 400 mg/day maintenance dose) was safely 
administered to 41 patients with moderately im- 
paired left ventricular function. Although only four 
patients had to discontinue the medication, 56 % de- 
veloped adverse effects within 30 months. Six of their 
patients required pacemaker implantation because 
of heart block, intraventricular conduction delays, or 
sick sinus syndrome, and an additional five patients 
developed sinus bradycardia (<50 beats/min). The 
absence of these side effects in our study may be at- 
tributable to our lower maintenance dose of amio- 
darone. 
Suppression of ventricular ectopy. Although low 
doses of amiodarone may be safe, they may also be 
ineffective. However, our study demonstrated that a 
low dose of amiodarone can significantly suppress 
both the frequency and complexity of ventricular ec- 
topy in patients with severe heart failure. Total ven- 
tricular ectopy was reduced by 75% in the majority 
of our patients within 1 month of initiating therapy 
and in 75% within 6 months. The incidence of 
asymptomatic ventricular tachycardia was reduced 
by 60% after 1 month and remained low during fol- 
low-up. Other investigators have also shown that 
low-dose amiodarone is effective in reducing ventric- 
ular ectopy in heart failure patients. Hamer et al.‘” 
reported that ventricular tachycardia was eliminated 
in 9 of 14 patients after 6 weeks of treatment with 
low-dose amiodarone. Neri et a1.13 found that the 
frequency of ventricular ectopy was suppressed by at 
least 80% in 30 of 41 patients after 3 weeks of treat- 
ment. Cleland et a1.r4 reported that exercise-induced 
ventricular tachycardia was suppressed in five of five 
patients receiving low-dose amiodarone. 
Survival. Despite low-dose amiodarone’s safety and 
efficacy in suppressing ventricular ectopy in patients 
with severe heart failure, we could not detect any re- 
duction in sudden death or prolongation of survival. 
Although the difference was not statistically signifi- 
cant, overall mortality after 1 year was paradoxically 
higher in the amiodarone group than in the control 
group-28 % versus 19 % . Similarly, there was no re- 
duction in sudden death among the amiodarone- 
treated patients compared with the controls. The 
absence of an effect of amiodarone on survival cannot 
be attributed to a baseline bias. Randomization of the 
study population divided the patients into two treat- 
ment groups with equivalent characteristics (Table 
I). The baseline variables that were correlated with 
mortality-the duration of heart failure symptoms 
and functional class-did not demonstrate a trend 
favoring survival in the placebo group. 
However, the absence of a beneficial effect of low- 
dose amiodarone on survival in our study can be at- 
tributed to the statistical power of the trial. The 
sample size calculation had assumed a much higher 
control mortality than what was observed. Given this 
low control mortality, reductions in mortality up to 
25% could not have been reliably detected. There are 
also other explanations for the absence of an im- 
provement in survival with low-dose amiodarone. 
Although our dose of amiodarone effectively sup- 
pressed ventricular ectopy, the degree of suppression 
was only partial and higher doses of the drug might 
have been more effective in not only suppressing ec- 
topy but also in preventing sudden death. However, 
since higher doses of amiodarone appear to be asso- 
ciated with increased toxicity, any reductions in sud- 
den deaths might be offset by increases in other 
causes of mortality. 
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Discrepancy between suppression of ventricular ec- 
topy and prevention of sudden death. The discrepancy 
between the marked reduction in ventricular ectopy 
among the amiodarone-treated patients in our study 
and the absence of any effect on survival is of inter- 
est. Both the frequency and complexity of spontane- 
ous ventricular ectopy have been used as indices of 
the risk of sudden death.i-*I This study demonstrates 
that reductions in asymptomatic ventricular ectopy 
and the risk of sudden death are not linearly related. 
A 75 % reduction in ectopy was not associated with a 
75% reduction in the incidence of sudden death. In 
fact, patients with >75% reductions in ventricular 
ectopy had poorer survival than patients with less 
suppression (Fig. 4). Investigators in the Cardiac Ar- 
rhythmia Suppression Trial (CAST)15 found a simi- 
lar discrepancy between arrhythmia suppression and 
survival in patients with asymptomatic ventricular 
ectopy following a myocardial infarction. In their 
study, patients treated with encainide or flecanide 
had a three- to fourfold higher incidence of sudden 
death than patients who received placebo despite ef- 
fective suppression of ventricular ectopy by both an- 
tiarrhythmic agents. Our trial and the CAST study 
emphasize the need to document the efficacy of an- 
tiarrhythmic drugs in reducing sudden deaths rather 
than in simply suppressing spontaneous ventricular 
ectopy. 
Bradyarrhythmias initiating sudden death. Another 
explanation for the discrepancy between suppression 
of ventricular ectopy and ineffective reduction of 
sudden death in this trial is that not all of the sud- 
den deaths in patients with heart failure are second- 
ary to malignant ventricular tachyarrhythmias. 
Although patients with congestive heart failure are 
often found to have frequent and complex ventricu- 
lar ectopy with episodes of asymptomatic ventricular 
tachycardia, there is little direct evidence demon- 
strating that ventricular tachyarrhythmias precipi- 
tate sudden death. Most patients die unexpectedly 
without documentation of the initiating arrhythmia. 
The largest group of heart failure patients dying 
suddenly with documentation of the initiating ar- 
rhythmia suggests that bradyarrhythmias precipi- 
tate sudden death more frequently than tachy- 
arrhythmias.16 Thus in this trial amiodarone may 
have been effective in reducing the frequency of sud- 
den death secondary to ventricular tachyarrhyth- 
mias, but because of its effects on nodal and ventric- 
ular conduction, it may have increased the incidence 
of sudden death due to bradyarrhythmias. 
Conclusion. Low-dose amiodarone can be safely 
administered to patients with severe heart failure 
and it significantly suppresses asymptomatic ven- 
Low-dose amiodurone in CHF 102 1 
tricular ectopy. However, despite arrhythmia sup- 
pression, low-dose amiodarone does not appear to 
have a major effect (>25 % ) in reducing the incidence 
of sudden death. Larger trials will be required to de- 
finitively determine the effect of low-dose amio- 
darone on survival in this population. 
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